Spruce Biosciences, Inc.
Corticotropin releasing factor receptor antagonists
Last updated:
Abstract:
The present invention provides novel pharmaceutical compositions comprising-(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,- 5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).
Status:
Grant
Type:
Utility
Filling date:
25 Jun 2021
Issue date:
7 Jun 2022